Publications by authors named "Michael Prime"

Claim this Profile
C
Correction to "Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates".
Longbin Liu, Peter D Johnson, Matthew R Mills, Penelope A Turner, Michael E Prime

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin Aggregates.
Longbin Liu, Peter D Johnson, Matthew R Mills, Penelope A Turner, Michael E Prime

J Med Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiscale Richtmyer-Meshkov instability experiments to isolate the strain rate dependence of strength.
Michael B Prime, Saryu J Fensin, David R Jones, Joshua W Dyer, Daniel T Martinez

Phys Rev E· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Evaluation of [F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates.
Longbin Liu, Peter D Johnson, Michael E Prime, Vinod Khetarpal, Christopher J Brown

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Daniele Bertoglio, Jonathan Bard, Manuela Hessmann, Longbin Liu, Annette Gärtner, Michael E Prime

Sci Transl Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
Frank Herrmann, Manuela Hessmann, Sabine Schaertl, Karola Berg-Rosseburg, Christopher J Brown, Michael E Prime

Sci Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.
Longbin Liu, Peter D Johnson, Michael E Prime, Vinod Khetarpal, Matthew R Lee

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.
Longbin Liu, Michael E Prime, Matt R Lee, Vinod Khetarpal, Christopher J Brown

J Med Chem· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tantalum strength at extreme strain rates from impact-driven Richtmyer-Meshkov instabilities.
Michael B Prime, William T Buttler, Saryu J Fensin, David R Jones, Justin L Brown

Phys Rev E· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Leticia M Toledo-Sherman, Michael E Prime, Ladislav Mrzljak, Maria G Beconi, Alan Beresford

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
Dirk Winkler, Maria Beconi, Leticia M Toledo-Sherman, Michael Prime, Andreas Ebneth

J Biomol Screen· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
Maria G Beconi, Dawn Yates, Kathryn Lyons, Kim Matthews, Steve Clifton, Michael Prime

Drug Metab Dispos· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.
John Wityak, Michael E Prime, Frederick A Brookfield, Stephen M Courtney, Sayeh Erfan

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.
Michael E Prime, Frederick A Brookfield, Stephen M Courtney, Simon Gaines, Richard W Marston

ACS Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
Michael E Prime, Ole A Andersen, John J Barker, Mark A Brooks, Robert K Y Cheng

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Michael E Prime, Stephen M Courtney, Frederick A Brookfield, Richard W Marston, Victoria Walker

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
Sabine Schaertl, Michael Prime, John Wityak, Celia Dominguez, Ignacio Munoz-Sanjuan

J Biomol Screen· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A versatile, non-biomimetic route to the preussomerins: syntheses of (+/-)-preussomerins F, K and L.
Ernesto Quesada, Martin Stockley, Jacques P Ragot, Michael E Prime, Adrian C Whitwood

Org Biomol Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis